By now, it seems that tumor mutational burden together with T cell-inflamed gene expression profile exhibit the greatest predictive utility in identifying responders and nonresponders to anti PD-1 therapy, as shown in a large study in >300 patient samples with advanced solid tumors and melanoma (representing approx. 30% of the tested samples) from four KEYNOTE clinical trials [255]. This evidence concerns the gene PDCD1 and neoplasm.